NYMC Faculty Publications
Point-of-Care Serodiagnostic Test for Early-Stage Lyme Disease Using a Multiplexed Paper-Based Immunoassay and Machine Learning
DOI
10.1021/acsnano.9b08151
Journal Title
ACS Nano
First Page
229
Last Page
240
Document Type
Article
Publication Date
1-28-2020
Department
Pathology, Microbiology and Immunology
Abstract
Caused by the tick-borne spirochete Borrelia burgdorferi, Lyme disease (LD) is the most common vector-borne infectious disease in North America and Europe. Though timely diagnosis and treatment are effective in preventing disease progression, current tests are insensitive in early stage LD, with a sensitivity of $400/test) and extended sample-to-answer timelines (>24 h). To address these challenges, we created a cost-effective and rapid point-of-care (POC) test for early-stage LD that assays for antibodies specific to seven Borrelia antigens and a synthetic peptide in a paper-based multiplexed vertical flow assay (xVFA). We trained a deep-learning-based diagnostic algorithm to select an optimal subset of antigen/peptide targets and then blindly tested our xVFA using human samples (N(+) = 42, N(-) = 54), achieving an area-under-the-curve (AUC), sensitivity, and specificity of 0.950, 90.5%, and 87.0%, respectively, outperforming previous LD POC tests. With batch-specific standardization and threshold tuning, the specificity of our blind-testing performance improved to 96.3%, with an AUC and sensitivity of 0.963 and 85.7%, respectively.
Recommended Citation
Joung, H., Ballard, Z. S., Wu, J., Tseng, D. K., Teshome, H., Zhang, L., Horn, E. J., Arnaboldi, P. M., Dattwyler, R. J., Garner, O. B., Di Carlo, D., & Ozcan, A. (2020). Point-of-Care Serodiagnostic Test for Early-Stage Lyme Disease Using a Multiplexed Paper-Based Immunoassay and Machine Learning. ACS Nano, 14 (1), 229-240. https://doi.org/10.1021/acsnano.9b08151
